文献速递流行病学与生物统计组学、生物样本库与精准医学基础与转化研究

中国2型糖尿病患者血糖进展的肥胖、临床与遗传预测因素:基于香港糖尿病登记与生物样本库的队列研究

Obesity, clinical, and genetic predictors for glycemic progression in Chinese patients with type 2 diabetes: A cohort study using the Hong Kong Diabetes Register and Hong Kong Diabetes Biobank.
PubMed 文献 · PLoS Med · 2020-07-28

该研究前瞻性随访7091例未使用胰岛素的香港华人2型糖尿病患者,定义血糖进展为需持续胰岛素治疗或两种口服降糖药下连续两次HbA1c≥8.5%,中位随访8.8年。结果显示血糖进展发生率48.0/1000人年,BMI极端值、高HbA1c、诊断年龄早、微血管并发症、高甘油三酯和吸烟是独立预测因素,包含123个T2D风险变异的PRS也预测胰岛素治疗快速进展。

要点

  • 血糖进展年发生率约5%,BMI极端值和高HbA1c是重要预测因素。
  • 诊断年龄早、微血管并发症、高甘油三酯和吸烟独立预测血糖进展。
  • 123个T2D风险变异的PRS预测胰岛素治疗快速进展,BMI相关PRS不预测。

核心结论

  • 约5%的T2D患者每年口服降糖药失效,可修饰和遗传风险因素独立关联血糖进展,有助于识别高危患者早期强化控制。

研究设计与样本

  • 1995-2007年前瞻性随访7091例未使用胰岛素的华人T2D患者,中位随访8.8年,并在香港糖尿病生物样本库多中心队列中验证。

主要发现

  • 血糖进展发生率为48.0(95%CI 46.3-49.8)/1000人年,2519例开始胰岛素治疗。
  • 多因素Cox分析显示诊断年龄早、微血管并发症、高甘油三酯和吸烟是独立预测因素。
  • 123个T2D风险变异的PRS预测胰岛素治疗快速进展(HR 1.07 [95%CI 1.03-1.12]每SD,P=0.001),验证队列HR 1.24(95%CI 1.06-1.46)每SD,P=0.008。
  • 63个BMI相关变异的PRS预测BMI(beta 0.312 [SE 0.057]每SD,P=5.84×10-8)但不预测血糖进展(HR 1.01 [95%CI 0.96-1.05]每SD,P=0.747)。

关键数值与推荐

  • 血糖进展定义为需持续胰岛素治疗或两种及以上口服降糖药下连续两次HbA1c≥8.5%。

临床怎么用

  • 对具有可修饰和遗传风险因素的高危T2D患者,可考虑早期强化多因素控制以预防血糖进展。

局限性

  • 可能存在T2D误诊,验证队列缺乏随访期间详细用药数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Type 2 diabetes (T2D) is a progressive disease whereby there is often deterioration in glucose control despite escalation in treatment. There is significant heterogeneity to this progression of glycemia after onset of diabetes, yet the factors that influence glycemic progression are not well understood. Given the tremendous burden of diabetes in the Chinese population, and limited knowledge on factors that influence glycemia, we aim to identify the clinical and genetic predictors for glycemic progression in Chinese patients with T2D. METHODS AND FINDINGS: In 1995-2007, 7,091 insulin-naïve Chinese patients (mean age 56.8 ± 13.3 [SD] years; mean age of T2D onset 51.1 ± 12.7 years; 47% men; 28.4% current or ex-smokers; median duration of diabetes 4 [IQR: 1-9] years; mean HbA1c 7.4% ± 1.7%; mean body mass index [BMI] 25.3 ± 4.0 kg/m2) were followed prospectively in the Hong Kong Diabetes Register. We examined associations of BMI and other clinical and genetic factors with glycemic progression defined as requirement of continuous insulin treatment, or 2 consecutive HbA1c ≥8.5% while on ≥2 oral glucose-lowering drugs (OGLDs), with validation in another multicenter cohort of Hong Kong Diabetes Biobank. During a median follow-up period of 8.8 (IQR: 4.8-13.3) years, incidence of glycemic progression was 48.0 (95% confidence interval [CI] 46.3-49.8) per 1,000 person-years with 2,519 patients started on insulin. Among the latter, 33.2% had a lag period of 1.3 years before insulin was initiated. Risk of progression was associated with extremes of BMI and high HbA1c. On multivariate Cox analysis, early age at diagnosis, microvascular complications, high triglyceride levels, and tobacco use were additional independent predictors for glycemic progression. A polygenic risk score (PRS) including 123 known risk variants for T2D also predicted rapid progression to insulin therapy (hazard ratio [HR]: 1.07 [95% CI 1.03-1.12] per SD; P = 0.001), with validation in the replication cohort (HR: 1.24 [95% CI 1.06-1.46] per SD; P = 0.008). A PRS using 63 BMI-related variants predicted BMI (beta [SE] = 0.312 [0.057] per SD; P = 5.84 × 10-8) but not glycemic progression (HR: 1.01 [95% CI 0.96-1.05] per SD; P = 0.747). Limitations of this study include potential misdiagnosis of T2D and lack of detailed data of drug use during follow-up in the replication cohort. CONCLUSIONS: Our results show that approximately 5% of patients with T2D failed OGLDs annually in this clinic-based cohort. The independent associations of modifiable and genetic risk factors allow more precise identification of high-risk patients for early intensive control of multiple risk factors to prevent glycemic progression.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Jiang G, Luk AO, Tam CHT, et al. Obesity, clinical, and genetic predictors for glycemic progression in Chinese patients with type 2 diabetes: A cohort study using the Hong Kong Diabetes Register and Hong Kong Diabetes Biobank. PLoS Med. 2020. PMID: 32722720. doi:10.1371/journal.pmed.1003209

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。